Solar Degradation of Sulfamethazine Using rGO/Bi Composite Photocatalysts

This work was supported by the Spanish Ministry of Economy, Industry and Competitiveness and by FEDER (CTQ2016-80978-C2−1-R), and the authors thank to Dr. Isabel Guerra Tschuschke for the technical advice during the VP-SEM study at the CIC-UGR.Heterogeneous photocatalysts for water decontamination were obtained by the optimized synthesis of bismuth-functionalized reduced graphene oxide (rGO/Bi) using the Hummer method and microwave treatment. Sulfamethazine (SMZ) was used as model pollutant to evaluate the photocatalytic efficacy. Photocatalysts were characterized by VP-SEM, HRTEM, XDR, XPS, RAMAN, and FTIR analyses, which confirmed the effective reduction of GO to rGO and the presence of bismuth as a crystalline phase of Bi2O3 polydispersed on the surface. Their performance was influenced by the rGO/Bi ratio, microwave temperature, and treatment time. The as-obtained 5%rGO/Bi composite had the highest photocatalytic activity for SMZ degradation under visible light irradiation (λ > 400 nm), achieving 100% degradation after only 2 h of treatment. The degradation yield decreased with higher percentages of rGO. Accordingly, the rGO/Bi catalysts efficiently removed SMZ, showing a high photocatalytic activity, and remained unchanged after three treatment cycles; furthermore, cytotoxicity tests demonstrated the nontoxicity of the aqueous medium after SMZ degradation. These findings support the potential value of these novel composites as photocatalysts to selectively remove pollutants in water treatment plants.Spanish Ministry of Economy, Industry and Competitiveness CTQ2016-80978-C2-1-REuropean Union (EU) CTQ2016-80978-C2-1-

Comparative Study of the Oxidative Degradation of Different 4-Aminobenzene Sulfonamides in Aqueous Solution by Sulfite Activation in the Presence of Fe(0), Fe(II), Fe(III) or Fe(VI)

This study is focused on advanced oxidation technologies (AOTs) using the combined effect of Fe(0–VI)/sulfite systems, that produce mainly SO4 radicals, to remove di erent 4-aminobenzene sulfonamides (SAs), namely sulfamethazine, sulfadiazine, sulfamethizole, from aqueous solutions. Results obtained showed that neither sulfite nor iron alone is able to degrade SAs; however, the combined effect depends on the oxidation state of iron species whose effectiveness to activate sulfite to promote the degradation of SAs increased following this order: Fe(III) < Fe(II) < Fe(0) < Fe(VI). Using Fe(VI)/sulfite, the complete removal of SAs was obtained in 5 min largely surpassing the effectiveness of the other three systems. The sulfonamides’ removal percentage was markedly influenced by sulfite concentration and dissolved oxygen, which improved the generation of oxidant radicals. Response surface methodology was applied, and a quadratic polynomial model was obtained, which allowed us to determine the percentage of SAs degradation as a function of both the iron species and sulfite concentrations. The study of the influence of the water matrix on these AOTs revealed an inhibition of SAs’ removal percentage when using ground water. This is probably due to the presence of different anions, such as HCO3 -, Cl-, and SO4 2- in relatively high concentrations. According to the byproducts identified, the proposed degradation pathways include hydroxylation, SO2 extrusion, and different bond-cleavage processes. Cytotoxicity of degradation byproducts, using MTS assay with HEK 293 and J774 cell lines for the first time, did not show an inhibition in cell proliferation, sustaining the safety of the process.This research was funded by both Ministry of Science and Innovation of Spain, grant number CTQ2016-80978-C2-1-R, and CONACyT (Mexico), grant number 407494

Synthesis of controlled-size silver nanoparticles for the administration of methotrexate drug and its activity in colon and lung cancer cells

A controlled synthesis of methotrexate (MTX) silver nanoparticles (AgNPs-MTX) using borohydride and citrate as reduction and reduction/capping agents, respectively, was performed in order to obtain AgNPs-MTX conjugates with a narrow size distribution. Their characterization showed polydispersed spherical shape nanoparticles with a mean size around 13 nm and distribution range between 7–21 nm. The presence of MTX was confirmed by FTIR and EDX analysis. Spectroscopic determinations suggest the chemisorption of MTX through a carboxylic group (–COOH) onto AgNPs via the exchange with a citrate molecule. Drug loading capacities calculated for AgNPs synthesized using different amounts of MTX were 28, 31 and 40%. In vitro drug release tests depicted similar release profiles for all conjugated amounts releasing between 77 to 85% of the initial MTX loaded into the AgNPs. With respect to free MTX, the addition of the nanocarrier delayed its release and also changed its pharmacokinetics. Free MTX is released after 3 hours following a first order kinetic model, whereas in the presence of AgNPs, a fast initial release is observed during the first 5 hours, followed by a plateau after 24 hours. In this case, AgNPs-MTX fitted a Higuchi model, where its solubilization is controlled by a diffusion process. Results obtained from flow cytometry of different cell lines treated with AgNPs-MTX demonstrated the combined anticancer effect of both reagents, decreasing the percentage of living cells in a colon cancer cell line (HTC-116) down to 40% after 48 hours of exposure. This effect was weaker but still significant for a lung cancer cell line (A-549). Finally, a zebrafish assay with AgNPs-MTX did not show any significant cytotoxic effect, confirming thereby the reduction of systemic drug toxicity achieved by coupling MTX to AgNPs. This observed toxicity reduction in the zebrafish model implies also a probable improvement of the usage of AgNPs-MTX in chemotherapy against human cancers.The authors are grateful for the financial support of the Ministry of Science and Innovation (CTQ2016-80978-C2-1-R)

Masked polycythaemia vera: presenting features, response to treatment and clinical outcomes.

Masked polycythaemia vera (PV) has been proposed as a new entity with poorer outcome than overt PV. In this study, the initial clinical and laboratory characteristics, response to treatment and outcome of masked and overt PV were compared using red cell mass and haemoglobin or haematocrit levels for the distinction between both entities. Sixty-eight of 151 PV patients (45%) were classified as masked PV according to World Health Organisation diagnostic criteria, whereas 16 (11%) were classified as masked PV using the British Committee for Standards in Haematology (BCSH). In comparison with overt PV, a higher platelet count and a lower JAK2V617F allele burden at diagnosis were observed in masked PV. Patients with masked PV needed lower phlebotomies and responded faster to hydroxcarbamide than those with overt PV. Complete haematological response was more frequently achieved in masked than in overt PV (79% vs. 58%, P = 0.001). There were no significant differences in the duration of haematological response, the rate of resistance or intolerance to hydroxycarbamide and the probability of molecular response according to type of PV (masked vs. overt). Overall survival, rate of thrombosis and major bleeding, and probability of transformation was superimposable among patients with masked and overt PV.This work was supported by grants from the Spanish Health Ministry ‘Fondo de Investigación Sanitaria’, PI10/01807,PI13/00557, PI13/00393, AECC Cataluña 2011, Instituto de Salud Carlos III FEDER RD12/0036/0010, SGR2014 567,the ‘Xarxa de Bancs de Tumors sponsored by Pla Director d’Oncologia de Catalunya (XBTC)’. Anna Angona is currently supported by a research grant from RETICS RD12/0036/0010

Development Of New Equations To Quantify Muscle Mass And Prognosis In Intensive Care Unit (Icu) Patients: An Ancillary Study Of The Phase Angle Project

International audienc

miR-203 and miR-221 regulate SOCS1 and SOCS3 in essential thrombocythemia.

The biological basis of essential thrombocythemia (ET) patients lacking known mutations is still unknown. MicroRNAs (miRNA) regulate hematopoietic differentiation and are deregulated in several hematopoietic malignancies. However, miRNA expression in ET patients has been poorly explored. We performed miRNA profiling in platelets from 19 ET patients and 10 healthy controls. Hierarchical cluster analysis showed two well-separated clusters between patients and controls, indicating that ET platelets had a characteristic 70-miRNA signature (P<0.0001), 68 of which were downregulated. According to the mutational status, three differentially expressed miRNAs, miR-15a (P=0.045), miR-150 (P=0.001) and miR-519a (P=0.036), were identified. A 40-miRNA signature was identified characterizing JAK2V617F-positive ET patients. Eight genes, whose interaction with the miRNAs could activate the JAK/STAT pathway were identified. An inverse correlation was observed between miRNAs expression and their target genes for SOCS1 and miR-221, SOCS3 and miR-221, SOCS3 and miR-203, and PTPN11 and miR-23a. All three miRNAs were upregulated in JAK2V617F-negative ET patients. SOCS1 and SOCS3 were validated as targets of miR-221 and miR-203, respectively. In summary, our study shows that platelets from JAK2V617F-negative ET patients harbor a specific miRNA signature that can participate in the modulation of the JAK/STAT pathway through regulation of key genes as SOCS1 and SOCS3.This work was supported by grants from Instituto de Salud Carlos III FEDER(PI10/01807, PI13/00557, PI13/00393, RD12/0036/0010, PT13/0010/0005), 2014 SGR567, and the‘Xarxa de Bancs de tumors’sponsored by Pla Director d'Oncologia deCatalunya (XBTC). Concepción Fernández-Rodríguez received a fellowship from theMinistry of Economy and Competitiveness of Spain (PFIS grant FI11/00353)

Characterization of CD34+ hematopoietic progenitor cells in JAK2V617F and CALR-mutated myeloproliferative neoplasms.

Mutations in JAK2 or CALR are observed in patients with myeloproliferative neoplasms (MPN). To get further insight in the dynamics of the mutant clone, we assessed the mutant allele burden in hematopoietic stem cells (HSCs), hematopoietic progenitor cells (HPCs) and granulocytes from 138 patients [51 polycythemia vera (PV), 58 essential thrombocythemia (ET) and 29 myelofibrosis (MF)]. CALR-mutated ET patients harbored a higher mutant load at progenitor level than JAK2V617F-positive ET (HSCs: 39.9% vs 7.5% p<0.001, HPCs: 32.7% vs 7.7% p<0.001). Moreover, HSCs of CALR-mutated ET patients showed a similar mutational load than patients with CALR-mutated MF (39.9% vs 48.2%, p=0.17). Regarding JAK2V617F MPN, PV and ET patients showed a low mutational burden at progenitor level whereas in the myelofibrotic phase the dominance of the mutated clone was a constant finding. In conclusion, the size of the mutated clone in chronic phase MPN is different according to genotype with CALR-mutated ET showing a pattern similar to that observed in MF.This study was supported by grants from the Ministry of Health of Spain and Instituto de Salud Carlos III FEDER (FIS PI10/018087, PI13/00557, PI13/00393, RD12/0036/0010

Characterization of CD34+ hematopoietic progenitor cells in JAK2V617F and CALR-mutated myeloproliferative neoplasms.

Mutations in JAK2 or CALR are observed in patients with myeloproliferative neoplasms (MPN). To get further insight in the dynamics of the mutant clone, we assessed the mutant allele burden in hematopoietic stem cells (HSCs), hematopoietic progenitor cells (HPCs) and granulocytes from 138 patients [51 polycythemia vera (PV), 58 essential thrombocythemia (ET) and 29 myelofibrosis (MF)]. CALR-mutated ET patients harbored a higher mutant load at progenitor level than JAK2V617F-positive ET (HSCs: 39.9% vs 7.5% p<0.001, HPCs: 32.7% vs 7.7% p<0.001). Moreover, HSCs of CALR-mutated ET patients showed a similar mutational load than patients with CALR-mutated MF (39.9% vs 48.2%, p=0.17). Regarding JAK2V617F MPN, PV and ET patients showed a low mutational burden at progenitor level whereas in the myelofibrotic phase the dominance of the mutated clone was a constant finding. In conclusion, the size of the mutated clone in chronic phase MPN is different according to genotype with CALR-mutated ET showing a pattern similar to that observed in MF.This study was supported by grants from the Ministry of Health of Spain and Instituto de Salud Carlos III FEDER (FIS PI10/018087, PI13/00557, PI13/00393, RD12/0036/0010

Masked polycythaemia vera: presenting features, response to treatment and clinical outcomes.

Masked polycythaemia vera (PV) has been proposed as a new entity with poorer outcome than overt PV. In this study, the initial clinical and laboratory characteristics, response to treatment and outcome of masked and overt PV were compared using red cell mass and haemoglobin or haematocrit levels for the distinction between both entities. Sixty-eight of 151 PV patients (45%) were classified as masked PV according to World Health Organisation diagnostic criteria, whereas 16 (11%) were classified as masked PV using the British Committee for Standards in Haematology (BCSH). In comparison with overt PV, a higher platelet count and a lower JAK2V617F allele burden at diagnosis were observed in masked PV. Patients with masked PV needed lower phlebotomies and responded faster to hydroxcarbamide than those with overt PV. Complete haematological response was more frequently achieved in masked than in overt PV (79% vs. 58%, P = 0.001). There were no significant differences in the duration of haematological response, the rate of resistance or intolerance to hydroxycarbamide and the probability of molecular response according to type of PV (masked vs. overt). Overall survival, rate of thrombosis and major bleeding, and probability of transformation was superimposable among patients with masked and overt PV.This work was supported by grants from the Spanish Health Ministry ‘Fondo de Investigación Sanitaria’, PI10/01807,PI13/00557, PI13/00393, AECC Cataluña 2011, Instituto de Salud Carlos III FEDER RD12/0036/0010, SGR2014 567,the ‘Xarxa de Bancs de Tumors sponsored by Pla Director d’Oncologia de Catalunya (XBTC)’. Anna Angona is currently supported by a research grant from RETICS RD12/0036/0010